HIV-1 latency remains a formidable barrier towards virus eradication as therapeutic attempts to purge these reservoirs are so far unsuccessful. The pool of transcriptionally silent proviruses is established early in infection and persists for a lifetime, even when viral loads are suppressed below detection levels using anti-retroviral therapy. Upon therapy interruption the reservoir can re-establish systemic infection. Different cellular reservoirs that harbor latent provirus have been described. In this study we demonstrate that HIV-1 can also establish a silent integration in actively proliferating primary T lymphocytes. Co-culturing of these proliferating T lymphocytes with dendritic cells (DCs) activated the provirus from latency. Activ...
Abstract Background Eradication of HIV-1 from an infected individual cannot be achieved by current d...
BACKGROUND: Combination antiretroviral therapy (cART) is able to control HIV-1 viral replication, ho...
Background: Combination antiretroviral therapy (cART) is able to control HIV-1 viral replication, ho...
<div><p>HIV-1 latency remains a formidable barrier towards virus eradication as therapeutic attempts...
Combination antiretroviral therapy (cART) is able to control HIV-1 replication and prevent acquired ...
Combination antiretroviral therapy (cART) is able to control HIV-1 replication and prevent acquired ...
Latently infected resting CD4(+) T cells are a major barrier to HIV cure. Understanding how latency ...
Background: The latent HIV-1 reservoir in treated patients primarily consists of resting memory CD4 ...
Latently infected resting CD4(+) T cells are a major barrier to HIV cure. Understanding how latency ...
<div><p>Latently infected resting CD4<sup>+</sup> T cells are a major barrier to HIV cure. Understan...
<p><b>A</b>: Schematic time line of the latency assay. PBMCs were isolated from a healthy blood dono...
In this thesis we focus on the ability of HIV-1 to establish a latent provirus in proliferating T ce...
International audienceThe C-type lectin DC-SIGN expressed on immature dendritic cells (DCs) captures...
Latently infected CD4 T cells form a stable reservoir of HIV that leads to life-long viral persisten...
The latent reservoir of HIV is the major barrier to cure. Stimulation of latently-infected T cells r...
Abstract Background Eradication of HIV-1 from an infected individual cannot be achieved by current d...
BACKGROUND: Combination antiretroviral therapy (cART) is able to control HIV-1 viral replication, ho...
Background: Combination antiretroviral therapy (cART) is able to control HIV-1 viral replication, ho...
<div><p>HIV-1 latency remains a formidable barrier towards virus eradication as therapeutic attempts...
Combination antiretroviral therapy (cART) is able to control HIV-1 replication and prevent acquired ...
Combination antiretroviral therapy (cART) is able to control HIV-1 replication and prevent acquired ...
Latently infected resting CD4(+) T cells are a major barrier to HIV cure. Understanding how latency ...
Background: The latent HIV-1 reservoir in treated patients primarily consists of resting memory CD4 ...
Latently infected resting CD4(+) T cells are a major barrier to HIV cure. Understanding how latency ...
<div><p>Latently infected resting CD4<sup>+</sup> T cells are a major barrier to HIV cure. Understan...
<p><b>A</b>: Schematic time line of the latency assay. PBMCs were isolated from a healthy blood dono...
In this thesis we focus on the ability of HIV-1 to establish a latent provirus in proliferating T ce...
International audienceThe C-type lectin DC-SIGN expressed on immature dendritic cells (DCs) captures...
Latently infected CD4 T cells form a stable reservoir of HIV that leads to life-long viral persisten...
The latent reservoir of HIV is the major barrier to cure. Stimulation of latently-infected T cells r...
Abstract Background Eradication of HIV-1 from an infected individual cannot be achieved by current d...
BACKGROUND: Combination antiretroviral therapy (cART) is able to control HIV-1 viral replication, ho...
Background: Combination antiretroviral therapy (cART) is able to control HIV-1 viral replication, ho...